CompletedPhase 4

The Efficacy and Safety of Oral Oxcarbazepine 300-1200 mg/Day as Adjuvant Therapy in the Treatment of Bipolar Disorder I or II This Study is Not Being Conducted in the United States.

55 participantsStarted 2003-01

Plain-language summary

Bipolar disorder is a psychiatric illness with clinical characteristics of mixed mania, grandiose delusions, and suicidality. This study will investigate the efficacy a safety of oxcarbazepine in the treatment of patients with bipolar disorder type I or II.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * History of bipolar disorder type I or II Exclusion Criteria: * Other serious medical conditions * Treatment with antiepileptic medications Other protocol-defined inclusion/exclusion criteria may apply.

What they're measuring

Duration of remission

Trial details

NCT IDNCT00154323

SponsorNovartis

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2006-01

View on ClinicalTrials.gov More Bipolar Disorder trials